Home|Best-Bschool-in-india-2018

DSIJ Mindshare

This Small-Cap Pharma to Unlock Rs 279 Crore in Cash from Mumbai Property Sale This Small-Cap Pharma to Unlock Rs 279 Crore in Cash from Mumbai Property Sale

This Small-Cap Pharma to Unlock Rs 279 Crore in Cash from Mumbai Property Sale

Unichem Laboratories' decision to sell its Mumbai property boosts investor confidence as stock hits day's high of Rs 635.10, up 4.66 per cent. The buyer in this transaction is Macrotech Developers Limited

Abhishek Wani 0 115 Article rating: 5.0

Unichem Laboratories' decision to sell its Mumbai property boosts investor confidence as stock hits day's high of Rs 635.10, up 4.66 per cent. The buyer in this transaction is Macrotech Developers Limited

Read more
Pharma Stocks Under Pressure: Shares Drop Nearly 4 per cent Despite Diabetes and Obesity Drug Launch in UK Pharma Stocks Under Pressure: Shares Drop Nearly 4 per cent Despite Diabetes and Obesity Drug Launch in UK

Pharma Stocks Under Pressure: Shares Drop Nearly 4 per cent Despite Diabetes and Obesity Drug Launch in UK

With GLP-1 therapies expected to be a significant revenue driver in the future, Biocon aims to strengthen its footprint in this segment.

Abhishek Wani 0 74 Article rating: 4.3

With GLP-1 therapies expected to be a significant revenue driver in the future, Biocon aims to strengthen its footprint in this segment.

Read more
Small-Cap Pharma Stock Plunges as US Regulatory Letter Wipes Out Rs 938 Crore in Market Cap—But It’s Not All Bad News Small-Cap Pharma Stock Plunges as US Regulatory Letter Wipes Out Rs 938 Crore in Market Cap—But It’s Not All Bad News

Small-Cap Pharma Stock Plunges as US Regulatory Letter Wipes Out Rs 938 Crore in Market Cap—But It’s Not All Bad News

Despite the sharp decline, the regulatory setback isn't as severe as it seems—the letter only raises compliance concerns without halting operations or triggering an import alert.

Abhishek Wani 0 113 Article rating: 5.0

Despite the sharp decline, the regulatory setback isn't as severe as it seems—the letter only raises compliance concerns without halting operations or triggering an import alert.

Read more
US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

Abhishek Wani 0 137 Article rating: 5.0

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

Read more
Pharma Extends Crucial Support to Indices Amidst Broader Market Downturn, This Pharma Major Scaled Up 2.12 Per Cent Pharma Extends Crucial Support to Indices Amidst Broader Market Downturn, This Pharma Major Scaled Up 2.12 Per Cent

Pharma Extends Crucial Support to Indices Amidst Broader Market Downturn, This Pharma Major Scaled Up 2.12 Per Cent

The company Receives Establishment Inspection Report (EIR) from the U.S. FDA for Its Manufacturing Facility in Somerset, New Jersey

Abhishek Wani 0 154 Article rating: 4.5

The Company Receives Establishment Inspection Report (EIR) from the U.S. FDA for Its Manufacturing Facility in Somerset, New Jersey

Read more
RSS
1234
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual
BSE Enlistment No. 5307

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual
BSE Enlistment No. 1346

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList